NASDAQ:CLSD Clearside Biomedical Q3 2025 Earnings Report ProfileEarnings HistoryForecast Clearside Biomedical EPS ResultsActual EPS-$1.14Consensus EPS -$0.67Beat/MissMissed by -$0.47One Year Ago EPSN/AClearside Biomedical Revenue ResultsActual Revenue$0.20 millionExpected Revenue$0.09 millionBeat/MissBeat by +$113.00 thousandYoY Revenue GrowthN/AClearside Biomedical Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 14, 2025Conference Call Time7:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Clearside Biomedical Earnings HeadlinesClearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan SponsorJuly 14, 2026 | businesswire.comClearside Biomedical Faces Delisting After Bankruptcy FilingNovember 25, 2025 | msn.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 3 at 1:00 AM | Chaikin Analytics (Ad)Clearside Biomedical to pursue sale of business via Chapter 11 processNovember 24, 2025 | msn.comClearside Biomedical, Inc. Files Chapter 11 Bankruptcy to Pursue Asset Sale and Maximize Stakeholder ValueNovember 24, 2025 | quiverquant.comQClearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 ProcessNovember 24, 2025 | globenewswire.comSee More Clearside Biomedical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clearside Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearside Biomedical and other key companies, straight to your email. Email Address About Clearside BiomedicalClearside Biomedical (NASDAQ:CLSD) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for diseases affecting the back of the eye. The company’s proprietary SCS Microinjector® platform enables targeted delivery of therapeutics into the suprachoroidal space, a potential route to enhance local drug exposure while minimizing off-target effects. Clearside’s approach is designed to address a range of retinal disorders by directly depositing medication adjacent to choroid and retina. The company’s lead approved product is XIPERE® (triamcinolone acetonide injectable suspension), which has received U.S. Food and Drug Administration clearance for the treatment of macular edema associated with uveitis. In addition to XIPERE, Clearside has advanced several pipeline candidates, including CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration and other small-molecule and biologic programs leveraging the suprachoroidal route. These programs are in various stages of clinical development, targeting indications such as diabetic macular edema and wet AMD. Founded in 2010 and headquartered in Alpharetta, Georgia, Clearside Biomedical completed its initial public offering on the Nasdaq Stock Market under the ticker “CLSD.” The company is led by President and Chief Executive Officer Samir Melhem, who has overseen clinical and regulatory milestones, including FDA approval of XIPERE. Clearside continues to explore both U.S. and ex-U.S. partnerships to expand patient access to its suprachoroidal therapies.View Clearside Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation TestLilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
